γ-Herpesviruses and cellular signaling in AIDS-associated malignancies

Cancer Science

Volumn 98, Issue 9, 2007, Pages 1288-1296

  Noguchi, Kohji ^b   Fukazawa, Hidesuke ^b   Murakami, Yuko ^c   Takahashi, Naoko ^c   Yamagoe, Satoshi ^c   Uehara, Yoshimasa ^a,d  

^a NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^b KEIO UNIVERSITY   (Japan)

^c KUMAMOTO UNIVERSITY   (Japan)

^d IWATE MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D; EPSTEIN BARR VIRUS ANTIGEN 1; EPSTEIN BARR VIRUS ANTIGEN 2; FLICE INHIBITORY PROTEIN; G PROTEIN COUPLED RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON REGULATORY FACTOR 1; INTERFERON REGULATORY FACTOR 2; INTERFERON REGULATORY FACTOR 3; INTERLEUKIN 6; KAPOSIN; LATENT MEMBRANE PROTEIN 1; LATENT MEMBRANE PROTEIN 2; MITOGEN ACTIVATED PROTEIN KINASE; NOTCH RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BART; PROTEIN EBER; PROTEIN EBNA3A; PROTEIN EBNA3B; PROTEIN EBNA3C; PROTEIN KINASE B; PROTEIN LANA 1; UNCLASSIFIED DRUG; VIRUS DNA; VIRUS PROTEIN; WNT PROTEIN;

AIDS RELATED COMPLEX; ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; APOPTOSIS; BURKITT LYMPHOMA; CARCINOGENESIS; CELL CYCLE REGULATION; DISEASE ASSOCIATION; DNA BINDING; DNA REPLICATION; EPSTEIN BARR VIRUS; HODGKIN DISEASE; HOST CELL; HUMAN; HUMAN HERPESVIRUS 8; KAPOSI SARCOMA; LYMPHOMA; MALIGNANT TRANSFORMATION; MOLECULAR MECHANICS; NASOPHARYNX CARCINOMA; NONHODGKIN LYMPHOMA; NONHUMAN; PATHOGENESIS; PERSISTENT INFECTION; PRIMARY EFFUSION LYMPHOMA; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; T CELL LYMPHOMA; TARGET CELL; VIRUS CELL INTERACTION; VIRUS GENE; VIRUS LATENCY; VIRUS REPLICATION; VIRUS SURVIVAL;

ANIMALS; APOPTOSIS; HERPESVIRUS 4, HUMAN; HERPESVIRUS 8, HUMAN; HUMANS; LYMPHOMA, AIDS-RELATED; SARCOMA, KAPOSI; SIGNAL TRANSDUCTION;

EID: 34547756469     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2007.00555.x     Document Type: Review

References (102)

1. Boshoff C, Weiss R. AIDS-related malignancies. Nat Rev Cancer 2002; 2: 373-82.
2. Damania B. Oncogenic gamma-herpesviruses: Comparison of viral proteins involved in tumorigenesis. Nat Rev Microbiol 2004; 2: 656-68.
3. Chang Y, Cesarman E, Pessin MS et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 1994; 266: 1865-9.
4. Katano H, Sato Y, Kurata T et al. High expression of HHV-8-encoded ORF73 protein in spindle-shaped cells of Kaposi's sarcoma. Am J Pathol 1999; 155: 47-52.
5. Boshoff C, Schulz TF, Kennedy MM et al. Kaposi's sarcoma-associated herpesvirus infects endothelial and spindle cells. Nat Med 1995; 1: 1274-8.
6. Hayward GS. Initiation of angiogenic Kaposi's sarcoma lesions. Cancer Cell 2003; 3: 1-3.
7. Pati S, Foulke JS Jr, Barabitskaya O et al. Human herpesvirus 8-encoded vGPCR activates nuclear factor of activated T cells and collaborates with human immunodeficiency virus type 1 Tat. J Virol 2003; 77: 5759-73.
8. Barillari G, Sgadari C, Palladino C et al. Inflammatory cytokines synergize with the HIV-1 Tat protein to promote angiogenesis and Kaposi's sarcoma via induction of basic fibroblast growth factor and the alpha v beta 3 integrin. J Immunol 1999; 163: 1929-35.
9. Aoki Y, Tosato G. HIV-1 Tat enhances Kaposi sarcoma-associated herpesvirus (KSHV) infectivity. Blood 2004; 104: 810-14.
10. Thorley-Lawson DA. Epstein-Barr virus: Exploiting the immune system. Nat Rev Immunol 2001; 1: 75-82.
11. Voo KS, Fu T, Wang HY et al. Evidence for the presentation of major histocompatibility complex class I-restricted Epstein-Barr virus nuclear antigen 1 peptides to CD8 + T lymphocytes. J Exp Med 2004; 199: 459-70.
12. Levitskaya J, Coram M, Levitsky V et al. Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature 1995; 375: 685-8.
13. Yin Y, Manoury B, Fahraeus R. Self-inhibition of synthesis and antigen presentation by Epstein-Barr virus-encoded EBNA1. Science 2003; 301: 1371-4.
14. Soulier J, Grollet L, Oksenhendler E et al. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood 1995; 86: 1276-80.
15. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med 2004; 10: 789-99.
16. Tsuruo T, Naito M, Tomida A et al. Molecular targeting therapy of cancer: Drug resistance, apoptosis and survival signal. Cancer Sci 2003; 94: 15-21.
17. Yates JL, Warren N, Sugden B. Stable replication of plasmids derived from Epstein-Barr virus in various mammalian cells. Nature 1985; 313: 812-15.
18. Hu J, Garber AC, Renne R. The latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus supports latent DNA replication in dividing cells. J Virol 2002; 76: 11 677-87.
19. Wang J, Sugden B. Origins of bidirectional replication of Epstein-Barr virus: Models for understanding mammalian origins of DNA synthesis. J Cell Biochem 2005; 94: 247-56.
20. Goldsmith K, Bendell L, Frappier L. Identification of EBNA1 amino acid sequences required for the interaction of the functional elements of the Epstein-Barr virus latent origin of DNA replication. J Virol 1993; 67: 3418-26.
21. Bochkarev A, Barwell JA, Pfuetzner RA et al. Crystal structure of the DNA-binding domain of the Epstein-Barr virus origin-binding protein, EBNA1, bound to DNA. Cell 1996; 84: 791-800.
22. Bashaw JM, Yates JL. Replication from oriP of Epstein-Barr virus requires exact spacing of two bound dimers of EBNA1 which bend DNA. J Virol 2001; 75: 10 603-11.
23. Schepers A, Ritzi M, Bousset K et al. Human origin recognition complex binds to the region of the latent origin of DNA replication of Epstein-Barr virus. EMBO J 2001; 20: 4588-602.
24. Dhar SK, Yoshida K, Machida Y et al. Replication from oriP of Epstein-Barr virus requires human ORC and is inhibited by geminin. Cell 2001; 106: 287-96.
25. Noguchi K, Vassilev A, Ghosh S et al. The BAH domain facilitates the ability of human Orc1 protein to activate replication origins in vivo. EMBO J 2006; 25: 5372-82.
26. Deng Z, Lezina L, Chen CJ et al. Telomeric proteins regulate episomal maintenance of Epstein-Barr virus origin of plasmid replication. Mol Cell 2002; 9: 493-503.
27. Rawlins DR, Milman G, Hayward SD et al. Sequence-specific DNA binding of the Epstein-Barr virus nuclear antigen (EBNA-1) to clustered sites in the plasmid maintenance region. Cell 1985; 42: 859-68.
28. Reisman D, Sugden B. trans activation of an Epstein-Barr viral transcriptional enhancer by the Epstein-Barr viral nuclear antigen 1. Mol Cell Biol 1986; 6: 3838-46.
29. Lim C, Sohn H, Lee D et al. Functional dissection of latency-associated nuclear antigen 1 of Kaposi's sarcoma-associated herpesvirus involved in latent DNA replication and transcription of terminal repeats of the viral genome. J Virol 2002; 76: 10 320-31.
30. Hu J, Renne R. Characterization of the minimal replicator of Kaposi's sarcoma-associated herpesvirus latent origin. J Virol 2005; 79: 2637-42.
31. Verma SC, Choudhuri T, Robertson ES. The minimal replicator element of KSHV terminal repeat supports replication in a semi-conservative and cell cycle dependent manner. J Virol 2007; 81: 3402-13.
32. Barbera AJ, Chodaparambil JV, Kelley-Clarke B et al. The nucleosomal surface as a docking station for Kaposi's sarcoma herpesvirus LANA. Science 2006; 311: 856-61.
33. Komatsu T, Ballestas ME, Barbera AJ et al. KSHV LANA1 binds DNA as an oligomer and residues N-terminal to the oligomerization domain are essential for DNA binding, replication, and episome persistence. Virology 2004; 319: 225-36.
34. Stedman W, Deng Z, Lu F et al. ORC, MCM, and histone hyperacetylation at the Kaposi's sarcoma-associated herpesvirus latent replication origin. J Virol 2004; 78: 12 566-75.
35. Verma SC, Choudhuri T, Kaul R et al. Latency-associated nuclear antigen (LANA) of Kaposi's sarcoma-associated herpesvirus interacts with origin recognition complexes at the LANA binding sequence within the terminal repeats. J Virol 2006; 80: 2243-56.
36. Ohsaki E, Ueda K, Sakakibara S et al. Poly (ADP-ribose) polymerase 1 binds to Kaposi's sarcoma-associated herpesvirus (KSHV) terminal repeat sequence and modulates KSHV replication in latency. J Virol 2004; 78: 9936-46.
37. Lan K, Kuppers DA, Verma SC et al. Induction of Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen by the lytic transactivator RTA. a novel mechanism for establishment of latency. J Virol 2005; 79: 7453-65.
38. Li M, Lee H, Yoon DW et al. Kaposi's sarcoma-associated herpesvirus encodes a functional cyclin. J Virol 1997; 71: 1984-91.
39. Verschuren EW, Jones N, Evan GI. The cell cycle and how it is steered by Kaposi's sarcoma-associated herpesvirus cyclin. J General Virol 2004; 85: 1347-61.
40. Van Dross R, Yao S, Asad S et al. Constitutively active K-cyclin/cdk6 kinase in Kaposi sarcoma-associated herpesvirus-infected cells. J Natl Cancer Inst 2005; 97: 656-66.
41. Kaldis P, Ojala PM, Tong L et al. CAK-independent activation of CDK6 by a viral cyclin. Mol Biol Cell 2001; 12: 3987-99.
42. Ellis M, Chew YP, Fallis L et al. Degradation of p27 (Kip) cdk inhibitor triggered by Kaposi's sarcoma virus cyclin-cdk6 complex. EMBO J 1999; 18: 644-53.
43. Mann DJ, Child ES, Swanton C et al. Modulation of p27 (Kip1) levels by the cyclin encoded by Kaposi's sarcoma-associated herpesvirus. EMBO J 1999; 18: 654-63.
44. Sarek G, Jarviluoma A, Ojala PM. KSHV viral cyclin inactivates p27KIP1 through Ser10 and Thr187 phosphorylation in proliferating primary effusion lymphomas. Blood 2006; 107: 725-32.
45. Jarviluoma A, Child ES, Sarek G et al. Phosphorylation of the cyclin-dependent kinase inhibitor p21Cip1 on serine 130 is essential for viral cyclin-mediated bypass of a p21Cip1-imposed G1 arrest. Mol Cell Biol 2006; 26: 2430-40.
46. Swanton C, Mann DJ, Fleckenstein B et al. Herpes viral cyclin/Cdk6 complexes evade inhibition by CDK inhibitor proteins. Nature 1997; 390: 184-7.
47. Talbot SJ, Weiss RA, Kellam P et al. Transcriptional analysis of human herpesvirus-8 open reading frames 71, 72, 73, K14, and 74 in a primary effusion lymphoma cell line. Virology 1999; 257: 84-94.
48. Friborg J Jr, Kong W, Hottiger MO et al. p53 inhibition by the LANA protein of KSHV protects against cell death. Nature 1999; 402: 889-94.
49. Radkov SA, Kellam P, Boshoff C. The latent nuclear antigen of Kaposi sarcoma-associated herpesvirus targets the retinoblastoma-E2F pathway and with the oncogene Hras transforms primary rat cells. Nat Med 2000; 6: 1121-7.
50. Katano H, Sato Y, Kurata T et al. Expression and localization of human herpesvirus 8-encoded proteins in primary effusion lymphoma, Kaposi's sarcoma, and multicentric Castleman's disease. Virology 2000; 269: 335-44.
51. Fakhari FD, Jeong JH, Kanan Y et al. The latency-associated nuclear antigen of Kaposi sarcoma-associated herpesvirus induces B cell hyperplasia and lymphoma. J Clin Invest 2006; 116: 735-42.
52. Shin YC, Nakamura H, Liang X et al. Inhibition of the ATM/p53 signal transduction pathway by Kaposi's sarcoma-associated herpesvirus interferon regulatory factor 1. J Virol 2006; 80: 2257-66.
53. Liu L, Eby MT, Rathore N et al. The human herpes virus 8-encoded viral FLICE inhibitory protein physically associates with and persistently activates the Ikappa B kinase complex. J Biol Chem 2002; 277: 13 745-51.
54. Field N, Low W, Daniels M et al. KSHV vFLIP binds to IKK-gamma to activate IKK. J Cell Sci 2003; 116: 3721-8.
55. Mosialos G, Birkenbach M, Yalamanchili R et al. The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. Cell 1995; 80: 389-99.
56. Izumi KM, Kieff ED. The Epstein-Barr virus oncogene product latent membrane protein 1 engages the tumor necrosis factor receptor-associated death domain protein to mediate B lymphocyte growth transformation and activate NF-kappaB. Proc Natl Acad Sci USA 1997; 94: 12 592-7.
57. Sylla BS, Hung SC, Davidson DM et al. Epstein-Barr virus-transforming protein latent infection membrane protein 1 activates transcription factor NF-kappaB through a pathway that includes the NF-kappaB-inducing kinase and the IkappaB kinases IKKalpha and IKKbeta. Proc Natl Acad Sci USA 1998; 95: 10 106-11.
58. Kieser A, Kilger E, Gires O et al. Epstein-Barr virus latent membrane protein-1 triggers AP-1 activity via the c-Jun N-terminal kinase cascade. EMBO J 1997; 16: 6478-85.
59. An J, Sun Y, Sun R et al. Kaposi's sarcoma-associated herpesvirus encoded vFLIP induces cellular IL-6 expression: The role of the NF-kappaB and JNK/AP1 pathways. Oncogene 2003; 22: 3371-85.
60. Murono S, Inoue H, Tanabe T et al. Induction of cyclooxygenase-2 by Epstein-Barr virus latent membrane protein 1 is involved in vascular endothelial growth factor production in nasopharyngeal carcinoma cells. Proc Natl Acad Sci USA 2001; 98: 6905-10.
61. An J, Sun Y, Rettig MB. Transcriptional coactivation of c-Jun by the KSHV-encoded LANA. Blood 2004; 103: 222-8.
62. Chen SY, Lu J, Shih YC et al. Epstein-Barr virus latent membrane protein 2A regulates c-Jun protein through extracellular signal-regulated kinase. J Virol 2002; 76: 9556-61.
63. Lanier LL. Viral immunoreceptor tyrosine-based activation motif (ITAM) - mediated signaling in cell transformation and cancer. Trends Cell Biol 2006; 16: 388-90.
64. Wang L, Dittmer DP, Tomlinson CC et al. Immortalization of primary endothelial cells by the K1 protein of Kaposi's sarcoma-associated herpesvirus. Cancer Res 2006; 66: 3658-66.
65. Lagunoff M, Majeti R, Weiss A et al. Deregulated signal transduction by the K1 gene product of Kaposi's sarcoma-associated herpesvirus. Proc Natl Acad Sci USA 1999; 96: 5704-9.
66. Brinkmann MM, Glenn M, Rainbow L et al. Activation of mitogen-activated protein kinase and NF-kappaB pathways by a Kaposi's sarcoma-associated herpesvirus K15 membrane protein. J Virol 2003; 77: 9346-58.
67. Komano J, Maruo S, Kurozumi K et al. Oncogenic role of Epstein-Barr virus-encoded RNAs in Burkitt's lymphoma cell line Akata. J Virol 1999; 73: 9827-31.
68. Samanta M, Iwakiri D, Kanda T et al. EB virus-encoded RNAs are recognized by RIG-I and activate signaling to induce type I IFN. EMBO J 2006; 25: 4207-14.
69. Iwakiri D, Eizuru Y, Tokunaga M et al. Autocrine growth of Epstein-Barr virus-positive gastric carcinoma cells mediated by an Epstein-Barr virus-encoded small RNA. Cancer Res 2003; 63: 7062-7.
70. Mainou BA, Everly DN Jr, Raab-Traub N. Epstein-Barr virus latent membrane protein 1 CTAR1 mediates rodent and human fibroblast transformation through activation of PI3K. Oncogene 2005; 24: 6917-24.
71. Swart R, Ruf IK, Sample J et al. Latent membrane protein 2A-mediated effects on the phosphatidylinositol 3-Kinase/Akt pathway. J Virol 2000; 74: 10 838-45.
72. Morrison JA, Klingelhutz AJ, Raab-Traub N. Epstein-Barr virus latent membrane protein 2A activates beta-catenin signaling in epithelial cells. J Virol 2003; 77: 12 276-84.
73. Moody CA, Scott RS, Amirghahari N et al. Modulation of the cell growth regulator mTOR by Epstein-Barr virus-encoded LMP2A. J Virol 2005; 79: 5499-506.
74. Murakami Y, Yamagoe S, Noguchi K et al. Ets-1-dependent expression of vascular endothelial growth factor receptors is activated by latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus through interaction with Daxx. J Biol Chem 2006; 281: 28 113-21.
75. Tomlinson CC, Damania B. The K1 protein of Kaposi's sarcoma-associated herpesvirus activates the Akt signaling pathway. J Virol 2004; 78: 1918-27.
76. Montaner S, Sodhi A, Ramsdell AK et al. The Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor as a therapeutic target for the treatment of Kaposi's sarcoma. Cancer Res 2006; 66: 168-74.
77. Sodhi A, Chaisuparat R, Hu J et al. The TSC2/mTOR pathway drives endothelial cell transformation induced by the Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor. Cancer Cell 2006; 10: 133-43.
78. Montaner S, Sodhi A, Molinolo A et al. Endothelial infection with KSHV genes in vivo reveals that vGPCR initiates Kaposi's sarcomagenesis and can promote the tumorigenic potential of viral latent genes. Cancer Cell 2003; 3: 23-36.
79. Bais C, Van Geelen A, Eroles P et al. Kaposi's sarcoma associated herpesvirus G protein-coupled receptor immortalizes human endothelial cells by activation of the VEGF receptor-2/KDR. Cancer Cell 2003; 3: 131-43.
80. Cannon M, Philpott NJ, Cesarman E. The Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor has broad signaling effects in primary effusion lymphoma cells. J Virol 2003; 77: 57-67.
81. Paulsen SJ, Rosenkilde MM, Eugen-Olsen J et al. Epstein-Barr virus-encoded BILF1 is a constitutively active G protein-coupled receptor. J Virol 2005; 79: 536-46.
82. Fujimuro M, Hayward SD. Manipulation of glycogen-synthase kinase-3 activity in KSHV-associated cancers. J Mol Med 2004; 82: 223-31.
83. Kikuchi A. Tumor formation by genetic mutations in the components of the Wnt signaling pathway. Cancer Sci 2003; 94: 225-9.
84. Jang KL, Shackelford J, Seo SY et al. Up-regulation of beta-catenin by a viral oncogene correlates with inhibition of the seven in absentia homolog 1 in B lymphoma cells. Proc Natl Acad Sci USA 2005; 102: 18 431-6.
85. Fujimuro M, Wu FY, ApRhys C et al. A novel viral mechanism for dysregulation of beta-catenin in Kaposi's sarcoma-associated herpesvirus latency. Nat Med 2003; 9: 300-6.
86. Fujimuro M, Liu J, Zhu J et al. Regulation of the interaction between glycogen synthase kinase 3 and the Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen. J Virol 2005; 79: 10 429-41.
87. Fujimuro M, Hayward SD. The latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus manipulates the activity of glycogen synthase kinase-3beta. J Virol 2003; 77: 8019-30.
88. Rehman AO, Wang CY. Notch signaling in the regulation of tumor angiogenesis. Trends Cell Biol 2006; 16: 293-300.
89. Hsieh JJ, Hayward SD. Masking of the CBF1/RBPJ kappa transcriptional repression domain by Epstein-Barr virus EBNA2. Science 1995; 268: 560-3.
90. Henkel T, Ling PD, Hayward SD et al. Mediation of Epstein-Barr virus EBNA2 transactivation by recombination signal-binding protein J kappa. Science 1994; 265: 92-5.
91. Pegman PM, Smith SM, D'Souza BN et al. Epstein-Barr virus nuclear antigen 2 trans-activates the cellular antiapoptotic bfl-1 gene by a CBF1/RBPJ kappa-dependent pathway. J Virol 2006; 80: 8133-44.
92. Lukac DM, Renne R, Kirshner JR et al. Reactivation of Kaposi's sarcoma-associated herpesvirus infection from latency by expression of the ORF 50 transactivator, a homolog of the EBV R protein. Virology 1998; 252: 304-12.
93. Liang Y, Chang J, Lynch SJ et al. The lytic switch protein of KSHV activates gene expression via functional interaction with RBP-Jkappa (CSL), the target of the Notch signaling pathway. Genes Dev 2002; 16: 1977-89.
94. Lan K, Kuppers DA, Robertson ES. Kaposi's sarcoma-associated herpesvirus reactivation is regulated by interaction of latency-associated nuclear antigen with recombination signal sequence-binding protein Jkappa, the major downstream effector of the Notch signaling pathway. J Virol 2005; 79: 3468-78.
95. Lan K, Kuppers DA, Verma SC et al. Kaposi's sarcoma-associated herpesvirus-encoded latency-associated nuclear antigen inhibits lytic replication by targeting Rta: A potential mechanism for virus-mediated control of latency. J Virol 2004; 78: 6585-94.
96. Lan K, Murakami M, Choudhuri T et al. Intracellular-activated Notch1 can reactivate Kaposi's sarcoma-associated herpesvirus from latency. Virology 2006; 351: 393-403.
97. Cuconati A, White E. Viral homologs of BCL-2: Role of apoptosis in the regulation of virus infection. Genes Dev 2002; 16: 2465-78.
98. Sarid R, Sato T, Bohenzky RA et al. Kaposi's sarcoma-associated herpesvirus encodes a functional bcl-2 homologue. Nat Med 1997; 3: 293-8.
99. Henderson S, Huen D, Rowe M et al. Epstein-Barr virus-coded BHRF1 protein, a viral homologue of Bcl-2, protects human B cells from programmed cell death. Proc Natl Acad Sci USA 1993; 90: 8479-83.
100. Wang HW, Sharp TV, Koumi A et al. Characterization of an anti-apoptotic glycoprotein encoded by Kaposi's sarcoma-associated herpesvirus which resembles a spliced variant of human survivin. EMBO J 2002; 21: 2602-15.
101. Li M, Brooks CL, Kon N et al. A dynamic role of HAUSP in the p53-Mdm2 pathway. Mol Cell 2004; 13: 879-86.
102. Saridakis V, Sheng Y, Sarkari F et al. Structure of the p53 binding domain of HAUSP/USP7 bound to Epstein-Barr nuclear antigen 1 implications for EBV-mediated immortalization. Mol Cell 2005; 18: 25-36.